美迪西2023年度英國(guó)研討會(huì) (Medicilon’s 2023 Annual UK Symposium: New Approaches to Facilitate Drug Discovery) 將于當(dāng)?shù)貢r(shí)間4月21日舉辦。 此次活動(dòng)在英國(guó)劍橋科技園巴布拉漢姆研究園區(qū) (Babraham research campus) 進(jìn)行。我們期待您的光臨！

時(shí)間| Friday, April 21st,12:00-18:00 pm

地點(diǎn)| Babraham Research Campus, King's Hedges Room

演講嘉賓

Shaun McNulty博士，高級(jí)科學(xué)顧問

Shaun is an experienced drug discoverer with over 30 years of experience in the biotechnology and pharmaceutical sectors. He is an experienced biotechnology executive, specialising in drug development strategy and the successful transfer of drug candidates into clinical trials. Shaun obtained his doctorate in kinase-mediated signalling from the University of York and undertook post-doctoral research on neuronal signalling pathways at the University of Cambridge. He then held positions of increasing seniority for Pfizer and GSK, managing development teams and small molecule programmes for preclinical development. He moved into the Biotechnology sector in 2006, joining Syntaxin to direct their discovery portfolio. He then moved to ImmBio, directing scientific collaborations and fundraising. Shaun has worked as a biotech executive for 9 years first as Biosceptre’s CSO, then working for Inflection and Awakn Life Sciences. He worked in the contract research sector as a Director of Biology for Charles River.

戴學(xué)東 博士 國(guó)際研發(fā)服務(wù)部執(zhí)行副總裁

美國(guó)麻省理工大學(xué)有機(jī)化學(xué)博士，博士后，深耕于中樞神經(jīng)系統(tǒng)疾病、傳染病和腫瘤疾病化學(xué)藥物的研發(fā)20余載，對(duì)藥物發(fā)現(xiàn)過程中包括苗頭化合物的確定及優(yōu)化，以及成功發(fā)展到高質(zhì)量的臨床候選化合物有著深刻的理解和豐富的實(shí)踐經(jīng)驗(yàn)。戴學(xué)東博士參與主持研發(fā)的藥物有已上市藥物，如Horizant?/Regnite?；臨床藥物，如JNJ-75276617；臨床候選化合物，如Arbaclofen Placarbil，XP21279，XP23829等。

曹保紅 博士 藥理部副總裁

北京醫(yī)科大學(xué)醫(yī)學(xué)博士。曾在丹麥國(guó)家血清研究所、美國(guó)匹茲堡大學(xué)及匹茲堡兒童醫(yī)院、美國(guó)貝納羅亞研究所等從事研究工作，在Nature Cell Biology, Nature Biotechnology, Journal of Cell Biology 等國(guó)際頂級(jí)學(xué)術(shù)期刊發(fā)表論文多達(dá)24篇，所研究項(xiàng)目曾兩次獲得獲美國(guó)國(guó)立衛(wèi)生研究院重要課題（NIH R01）資助。加入美迪西之前，曹博士曾擔(dān)任藥明康德美國(guó)分公司免疫腫瘤學(xué)高級(jí)主任，MI Bioresearch（現(xiàn)由科文斯收購(gòu)）研究運(yùn)營(yíng)總監(jiān)，上海睿智化學(xué)研究有限公司、諾華（中國(guó)）生物醫(yī)學(xué)研究中心等的高級(jí)管理職務(wù)。超25年醫(yī)藥研發(fā)經(jīng)驗(yàn)，超10年團(tuán)隊(duì)管理經(jīng)驗(yàn)，曹博士在藥物發(fā)現(xiàn)領(lǐng)域造詣深厚，尤其在腫瘤疾病模型構(gòu)建和CAR-T細(xì)胞治療方面頗有建樹，是一位醫(yī)藥研發(fā)知識(shí)淵博、成績(jī)斐然的行業(yè)領(lǐng)軍人物。

Marshal Ma, 歐洲業(yè)務(wù)發(fā)展副總裁

Marshal Ma has over 30 years’ experience for international business and technology brokerage in the life sciences industry, facilitating and negotiating partnership deals among UK, Europe and Global biotech companies with China based large biopharmaceutical, healthcare and MedTech companies. Over the years Marshal Ma as MD of UK Cambridge based technology brokerage company, successfully negotiated many licensed partnership deals between European biotech companies and China biopharmaceutical companies. Since working with Medicilon on strategic alliance and business development project, Marshal combined China licensed partnership deal making with Medicilon CRO services to better serve biotech and pharma companies. Marshal worked on different preclinical projects commissioned by pharma, biotech and leading European CDMOs, coordinated with Medicilon research team to carry out successful PD, PK and safety studies with quality study reports delivered to meet the requirements of FDA, TGA, EMA and NMPA.

美迪西新分子類型聚合賦能平臺(tái)